StockData
Alaunos Therapeutics, Inc. logo

Alaunos Therapeutics, Inc. (TCRT) stock

TCRTNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 14, 2026Score 4/30
$1.72+0.06 (+3.61%)

Close on Nov 18, 2026Market cap $4.37MP/E –Yield –

Alaunos Therapeutics operating cash flow

Operating cash flow is the cash the business generates from its day-to-day operations.

Alaunos Therapeutics's operating cash flow for the twelve months ending Jun 30, 2026 was -$2.73M. For fiscal 2025 it was -$2.87M. The highest annual figure on record is -$10.00K in fiscal 2015.

Annual operating cash flow

PeriodPeriod endValueChange
FY2025Dec 31, 2025-$2.87M–
FY2024Dec 31, 2024-$4.97M–
FY2023Dec 31, 2023-$30.14M–
FY2022Dec 31, 2022-$29.23M–
FY2021Dec 31, 2021-$61.47M–
FY2020Dec 31, 2020-$57.01M–
FY2019Dec 31, 2019-$40.85M–
FY2018Dec 31, 2018-$49.46M–
FY2017Dec 31, 2017-$54.67M–
FY2016Dec 31, 2016-$58.33M–
FY2015Dec 31, 2015-$10.00K–
FY2014Dec 31, 2014-$36.65M–
FY2013Dec 31, 2013-$59.51M–
FY2012Dec 31, 2012-$78.83M–
FY2011Dec 31, 2011-$38.84M–
FY2010Dec 31, 2010-$19.69M–
FY2009Dec 31, 2009-$12.29M–

Quarterly operating cash flow

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026-$300.00K–
Q1 FY2026Mar 31, 2026-$1.03M–
Q4 FY2025Dec 31, 2025-$552.00K–
Q3 FY2025Sep 30, 2025-$844.00K–
Q2 FY2025Jun 30, 2025-$701.00K–
Q1 FY2025Mar 31, 2025-$772.00K–
Q4 FY2024Dec 31, 2024-$592.00K–
Q3 FY2024Sep 30, 2024-$781.00K–
Q2 FY2024Jun 30, 2024-$1.68M–
Q1 FY2024Mar 31, 2024-$1.92M–
Q4 FY2023Dec 31, 2023-$7.39M–
Q3 FY2023Sep 30, 2023-$6.37M–
Q2 FY2023Jun 30, 2023-$7.00M–
Q1 FY2023Mar 31, 2023-$9.38M–
Q4 FY2022Dec 31, 2022-$7.13M–
Q3 FY2022Sep 30, 2022-$6.15M–
Q2 FY2022Jun 30, 2022-$8.19M–
Q1 FY2022Mar 31, 2022-$7.77M–
Q4 FY2021Dec 31, 2021-$15.13M–
Q1 FY2021Jun 30, 2021-$36.77M–
Q4 FY2020Dec 31, 2020-$17.04M–
Q3 FY2020Sep 30, 2020-$16.07M–
Q2 FY2020Jun 30, 2020-$14.01M–
Q1 FY2020Mar 31, 2020-$9.91M–
Q4 FY2019Dec 31, 2019-$11.61M–
Q3 FY2019Sep 30, 2019-$10.93M–
Q2 FY2019Jun 30, 2019-$8.09M–
Q1 FY2019Mar 31, 2019-$10.23M–
Q4 FY2018Dec 31, 2018-$11.82M–
Q3 FY2018Sep 30, 2018-$8.51M–
Q2 FY2018Jun 30, 2018-$10.17M–
Q1 FY2018Mar 31, 2018-$18.96M–
Q4 FY2017Dec 31, 2017-$12.16M–
Q3 FY2017Sep 30, 2017-$12.71M–
Q2 FY2017Jun 30, 2017-$15.52M–
Q1 FY2017Mar 31, 2017-$14.28M–
Q4 FY2016Dec 31, 2016-$13.06M–
Q3 FY2016Sep 30, 2016-$14.11M–
Q2 FY2016Jun 30, 2016-$15.07M–

More Alaunos Therapeutics figures

See a number that looks wrong?